Results 191 to 200 of about 125,716 (297)

Effects of rifaximin in fructose-induced steatohepatitis in rats. [PDF]

open access: yesHepatol Forum
Celik NC   +6 more
europepmc   +1 more source

Changes in LXRα phosphorylation promote a novel diet-induced transcriptome that alters the transition from fatty liver to steatohepatitis [PDF]

open access: gold, 2017
Natalia Bécares   +17 more
openalex   +1 more source

Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT

open access: yesObesity, EarlyView.
ABSTRACT Objective This post hoc analysis assessed psychiatric changes with tirzepatide in adults with obesity, without known major psychopathology, from SURMOUNT‐1, SURMOUNT‐2, and SURMOUNT‐3. Methods In participants (N = 4056) treated with tirzepatide (5/10/15 mg or maximum tolerated dose 10/15 mg) versus placebo, depressive symptoms and suicidal ...
Thomas A. Wadden   +6 more
wiley   +1 more source

Bardoxolone methyl prevents metabolic dysfunction‐associated steatohepatitis by inhibiting macrophage infiltration [PDF]

open access: bronze
Kazuhiro Onuma   +5 more
openalex   +1 more source

Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates

open access: yesClinical Gastroenterology and Hepatology, 2019
Z. Younossi   +16 more
semanticscholar   +1 more source

Ashwagandha: Is It Safe? Part 2: A Preclinical Evidence Review

open access: yesPhytotherapy Research, EarlyView.
ABSTRACT The preclinical evidence for the safety of ashwagandha (Withania somnifera (L.) Dunal, AS) is reviewed, and its preparations (extracts) and constituents, from the general toxicity in animal models to in vitro and cell culture studies, which may elucidate mechanisms of action and explain clinical case reports.
Elizabeth M. Williamson, Thomas Brendler
wiley   +1 more source

Home - About - Disclaimer - Privacy